Key result
Calcification inhibitors protect against vascular calcification in peritoneal dialysis patients.
Answers are grounded in this paper and cite their sources.
The prevalence of cardiovascular diseases is high among patients with chronic kidney disease (CKD) and peritoneal dialysis (PD) patients, which increases morbidity and mortality in this population and represents a significant financial burden for both the patients and the healthcare systems. Vascular calcification (VC) is associated with increased morbidity and mortality and VC risk is higher in patients with CKD than in healthy individuals. Calcification inhibitors, compounds that inhibit VC, were discovered as a result of efforts to explain why some patients are spared. It was found that certain proteins (e.g., fetuin-A, osteopontin, osteoprotegerin, bone morphogenetic protein-7) inhibit calcification in dialysis patients. In this narrative review, we provide an overview of known calcification inhibitors, describe the relevant regulatory mechanisms, and discuss their relation to VC development in PD patients.
No takes yet. Share an insight, caveat, or question.
Olmaz et al. (2023) conducted a review in Vascular calcification and cardiovascular disease in chronic kidney disease and peritoneal dialysis patients. Vascular calcification inhibitors (e.g., fetuin-A, osteopontin, osteoprotegerin, bone morphogenetic protein-7) was evaluated on Vascular calcification development and cardiovascular events. Calcification inhibitors (fetuin-A, osteopontin, osteoprotegerin, BMP-7) inhibit vascular calcification in peritoneal dialysis patients (narrative review; no quantitative outcomes reported).
Synapse has enriched 10 related papers. Consider them for comparative context: